Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IKT Stock Summary
Top 10 Correlated ETFs
IKT
In the News
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
New Strong Buy Stocks for February 13th
IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.
Best Momentum Stocks to Buy for February 8th
POST, IKT and ACMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 8, 2023.
New Strong Buy Stocks for February 8th
IKT, POST, ASAN, ACMR and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2023.
New Strong Buy Stocks for February 6th
EGO, SBSI, CCS, TCBX and IKT have been added to the Zacks Rank #1 (Strong Buy) List on February 6, 2023.
New Strong Buy Stocks for January 31st
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Best Momentum Stocks to Buy for January 26th
PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.
New Strong Buy Stocks for January 26th
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2023 Earnings Conference Call November 15, 2023 8:00 AM ET Company Participants Alex Lobo - IR Milton Werner - CEO Joseph Frattaroli - CFO Conference Call Participants Edward White - H.C. Wainwright Operator Hello, and welcome to the Inhibikase Therapeutics Third Quarter 2023 Financial Results.
IKT Financial details
IKT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.03 | 0.82 | 0.51 | 1.02 | 0.03 | |
Net income per share | -1.61 | -4.22 | -2.1 | -4.88 | -4.26 | |
Operating cash flow per share | 0.54 | -0.25 | -0.83 | -4.71 | -4.13 | |
Free cash flow per share | 0.54 | -0.25 | -0.83 | -4.71 | -4.19 | |
Cash per share | 0.28 | 0.01 | 10.19 | 13.43 | 5.49 | |
Book value per share | -0.58 | -3.29 | 7.15 | 12.66 | 5.01 | |
Tangible book value per share | -0.58 | -3.29 | 7.15 | 12.66 | 5.01 | |
Share holders equity per share | -0.58 | -3.29 | 7.15 | 12.66 | 5.01 | |
Interest debt per share | 0.2 | 0.29 | 0.25 | 0.09 | 0.1 | |
Market cap | 79.34M | 80.99M | 56.67M | 26.77M | 12.61M | |
Enterprise value | 79.19M | 81.35M | 43.03M | -13.73M | 5.77M | |
P/E ratio | -36.86 | -14.09 | -19.69 | -1.81 | -0.7 | |
Price to sales ratio | 19.63 | 72.14 | 81.13 | 8.63 | 102.12 | |
POCF ratio | 110.96 | -239.41 | -50.18 | -1.87 | -0.73 | |
PFCF ratio | 110.96 | -239.41 | -50.18 | -1.87 | -0.72 | |
P/B Ratio | -101.98 | -18.04 | 5.79 | 0.7 | 0.6 | |
PTB ratio | -101.98 | -18.04 | 5.79 | 0.7 | 0.6 | |
EV to sales | 19.6 | 72.45 | 61.61 | -4.43 | 46.73 | |
Enterprise value over EBITDA | -37.32 | -14.28 | -15.27 | 0.93 | -0.32 | |
EV to operating cash flow | 110.76 | -240.46 | -38.1 | 0.96 | -0.33 | |
EV to free cash flow | 110.76 | -240.46 | -38.1 | 0.96 | -0.33 | |
Earnings yield | -0.03 | -0.07 | -0.05 | -0.55 | -1.42 | |
Free cash flow yield | 0.01 | 0 | -0.02 | -0.53 | -1.4 | |
Debt to equity | -0.3 | -0.08 | 0.03 | 0.01 | 0.02 | |
Debt to assets | 0.08 | 9.77 | 0.02 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.07 | -0.06 | 4.84 | 2.74 | 0.38 | |
Current ratio | 0.35 | 0.01 | 3.13 | 10.47 | 6.59 | |
Interest coverage | -69.96 | -229.44 | -95.86 | -741.16 | -243.49 | |
Income quality | -0.33 | 0.06 | 0.4 | 0.97 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | -0.01 | 0 | |
Sales general and administrative to revenue | 0.62 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.9 | 2.27 | 1.28 | 3.66 | 97.5 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | -1.97 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -36.18 | |
Stock based compensation to revenue | 0.16 | 1.28 | 0.82 | 0.49 | 3.71 | |
Graham number | 4.6 | 17.67 | 18.39 | 37.28 | 21.91 | |
ROIC | 3.9 | 1.39 | -0.28 | -0.38 | -0.83 | |
Return on tangible assets | -0.76 | -150.25 | -0.19 | -0.35 | -0.72 | |
Graham Net | -2.16 | -3.31 | 6.54 | 12.14 | 4.7 | |
Working capital | -2.37M | -4.22M | 10.06M | 38.42M | 20.68M | |
Tangible asset value | -777.97K | -4.49M | 9.78M | 38.42M | 21.04M | |
Net current asset value | -2.37M | -4.49M | 9.78M | 38.42M | 20.47M | |
Invested capital | -0.3 | -0.08 | 0.03 | 0.01 | 0.02 | |
Average receivables | 0 | 236.47K | 0 | 55.07K | 75.01K | |
Average payables | 0 | 977.97K | 1.36M | 1.41M | 1.12M | |
Average inventory | 0 | 0 | 0 | 53.5K | 612.31K | |
Days sales outstanding | 42.72 | 0 | 0 | 12.97 | 117.92 | |
Days payables outstanding | 0 | 143.23 | 702.67 | 35.02 | 62.5K | |
Days of inventory on hand | 0 | 0 | 0 | 3.44 | 60.68K | |
Receivables turnover | 8.54 | 0 | 0 | 28.15 | 3.1 | |
Payables turnover | 0 | 2.55 | 0.52 | 10.42 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 106.16 | 0.01 | |
ROE | 2.77 | 1.28 | -0.29 | -0.39 | -0.85 | |
Capex per share | 0 | 0 | 0 | 0 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.03 | 0.01 | 0.02 | 0.01 | |
Net income per share | -1.06 | -0.99 | -0.87 | -1.11 | -0.86 | |
Operating cash flow per share | -1.31 | -0.85 | -1.3 | -0.87 | -0.77 | |
Free cash flow per share | -1.36 | -0.8 | -1.3 | -0.88 | -0.77 | |
Cash per share | 6.31 | 5.49 | 5.61 | 4.01 | 3.15 | |
Book value per share | 5.98 | 5.01 | 5.52 | 3.72 | 2.81 | |
Tangible book value per share | 5.98 | 5.01 | 5.52 | 3.72 | 2.81 | |
Share holders equity per share | 5.98 | 5.01 | 5.52 | 3.72 | 2.81 | |
Interest debt per share | 0.09 | 0.1 | 0.12 | 0.14 | 0.05 | |
Market cap | 22.96M | 12.59M | 18.11M | 18.87M | 7.43M | |
Enterprise value | 17.55M | 5.76M | 14.48M | 17.26M | -7.17M | |
P/E ratio | -1.29 | -0.76 | -1.13 | -0.82 | -0.4 | |
Price to sales ratio | 3.15K | 102.02 | 280.7 | 162.07 | 93.33 | |
POCF ratio | -4.17 | -3.54 | -3.03 | -4.13 | -1.81 | |
PFCF ratio | -4.02 | -3.75 | -3.03 | -4.12 | -1.81 | |
P/B Ratio | 0.91 | 0.6 | 0.72 | 0.97 | 0.49 | |
PTB ratio | 0.91 | 0.6 | 0.72 | 0.97 | 0.49 | |
EV to sales | 2.41K | 46.63 | 224.41 | 148.26 | -90.05 | |
Enterprise value over EBITDA | -3.9 | -1.32 | -3.07 | -2.86 | 1.5 | |
EV to operating cash flow | -3.19 | -1.62 | -2.42 | -3.78 | 1.75 | |
EV to free cash flow | -3.08 | -1.72 | -2.42 | -3.77 | 1.75 | |
Earnings yield | -0.19 | -0.33 | -0.22 | -0.31 | -0.62 | |
Free cash flow yield | -0.25 | -0.27 | -0.33 | -0.24 | -0.55 | |
Debt to equity | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
Net debt to EBITDA | 1.2 | 1.57 | 0.77 | 0.27 | 3.06 | |
Current ratio | 8.71 | 6.59 | 10.37 | 8.04 | 6.4 | |
Interest coverage | -243.48 | -77.53 | -19.88 | -14.61 | 0 | |
Income quality | 1.22 | 0.83 | 1.33 | 0.79 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 408.95 | 24.74 | 44.24 | 38.96 | 40.54 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | -0.06 | 0 | 0 | 0 | |
Capex to revenue | -27.45 | 1.62 | 0 | -0.12 | 0 | |
Capex to depreciation | -119.08 | 39.7 | 0 | -0.09 | 0 | |
Stock based compensation to revenue | 13.96 | 0.81 | 1.91 | 1.07 | 1.63 | |
Graham number | 11.94 | 10.58 | 10.42 | 9.63 | 7.38 | |
ROIC | -0.17 | -0.19 | -0.16 | -0.31 | -0.31 | |
Return on tangible assets | -0.16 | -0.17 | -0.14 | -0.26 | -0.26 | |
Graham Net | 5.6 | 4.7 | 5.1 | 3.51 | 2.61 | |
Working capital | 24.77M | 20.68M | 24.96M | 19.25M | 14.81M | |
Tangible asset value | 25.14M | 21.04M | 25.32M | 19.46M | 15.02M | |
Net current asset value | 24.54M | 20.47M | 24.79M | 19.1M | 14.69M | |
Invested capital | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | |
Average receivables | 10.2K | 26.86K | 52.2K | 72.06K | 39.8K | |
Average payables | 820.83K | 966.2K | 1.06M | 856.61K | 744.35K | |
Average inventory | 925.74K | 1.03M | 1.02M | 674.18K | 212.61K | |
Days sales outstanding | 170.87 | 29.08 | 90 | 61.54 | 0 | |
Days payables outstanding | 41.83K | 20.55K | 17.12K | 426.33 | 10.07K | |
Days of inventory on hand | 49.92K | 19.95K | 16.47K | 240.39 | 0 | |
Receivables turnover | 0.53 | 3.1 | 1 | 1.46 | 0 | |
Payables turnover | 0 | 0 | 0.01 | 0.21 | 0.01 | |
Inventory turnover | 0 | 0 | 0.01 | 0.37 | 0 | |
ROE | -0.18 | -0.2 | -0.16 | -0.3 | -0.31 | |
Capex per share | -0.05 | 0.05 | 0 | 0 | 0 |
IKT Frequently Asked Questions
What is Inhibikase Therapeutics, Inc. stock symbol ?
Inhibikase Therapeutics, Inc. is a US stock , located in Atlanta of Ga and trading under the symbol IKT
What is Inhibikase Therapeutics, Inc. stock quote today ?
Inhibikase Therapeutics, Inc. stock price is $2.16 today.
Is Inhibikase Therapeutics, Inc. stock public?
Yes, Inhibikase Therapeutics, Inc. is a publicly traded company.